Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma. (Q51573223)

7 April 2018

title

Sellar Wegener Granulomatosis Masquerading as Cabergoline-Resistant Prolactinoma. (English)

1 reference

7 April 2018

author name string

Ilyas M Eli

1

1 reference

7 April 2018

Amol Raheja

2

1 reference

7 April 2018

Heather J Corn

3

1 reference

7 April 2018

Debra L Simmons

4

1 reference

7 April 2018

Cheryl Ann Palmer

5

1 reference

7 April 2018

William T Couldwell

6

1 reference

7 April 2018

publication date

10 August 2016

1 reference

7 April 2018

published in

World Neurosurgery

1 reference

7 April 2018

volume

95

1 reference

7 April 2018

page(s)

622.e1-622.e5

1 reference

7 April 2018

cites work

Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Wegener's granulomatosis: a review of clinical features and an update in diagnosis and treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Neurological involvement in Wegener's granulomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Cranial neuropathies in granulomatosis with polyangiitis (Wegener's): a case-based review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Pituitary involvement in granulomatosis with polyangiitis: report of 9 patients and review of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Diabetes insipidus as the presenting symptom of Wegener's granulomatosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Diabetes insipidus associated with Wegener's granulomatosis successfully treated with cyclophosphamide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Two cases of Wegener's granulomatosis involving the pituitary

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Pituitary dysfunction in granulomatosis with polyangiitis: the Mayo Clinic experience

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Wegener Granulomatosis: An Analysis of 158 Patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Wegener's granulomatosis: clinical manifestations, differential diagnosis, and management of ocular and systemic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Improved outcome in 445 patients with Wegener's granulomatosis in a German vasculitis center over four decades

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Treatment of granulomatosis with polyangiitis (Wegener's).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

7 January 2021

Small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Clinic manifestations in granulomatosis with polyangiitis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Wegener's granulomatosis: cutaneous and oral mucosal disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

An audit of ANCA in routine clinical practice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

7 January 2021

Wegener's granulomatosis

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

The American College of Rheumatology 1990 criteria for the classification of Wegener's granulomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Neurological involvement in Wegener's granulomatosis: an analysis of 324 consecutive patients at the Mayo Clinic

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Pituitary involvement in Wegener's granulomatosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Do the limits of serum prolactin in disconnection hyperprolactinaemia need re-definition? A study of 226 patients with histologically verified non-functioning pituitary macroadenoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Diagnostic pitfalls of hyperprolactinemia: the importance of sequential pituitary imaging

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Pituitary involvement in Wegener's granulomatosis: unusual biochemical findings and severe malnutrition.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

Hypophyseal Wegener's granulomatosis presenting by visual field constriction without hypopituitarism.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.WNEU.2016.07.108

10.1016/J.WNEU.2016.07.108

7 January 2021

Identifiers

DOI

1 reference

7 April 2018

PubMed ID

27521731

1 reference

7 April 2018